Literature DB >> 19420982

Lysophosphatidic acid stimulates cell growth by different mechanisms in SKOV-3 and Caov-3 ovarian cancer cells: distinct roles for Gi- and Rho-dependent pathways.

Jillian H Hurst1, Shelley B Hooks.   

Abstract

BACKGROUND/AIMS: Lysophosphatidic acid (LPA) is an autocrine growth signal critical to the initiation and progression of ovarian cancer. In the current study, we investigated the receptors and signaling cascades responsible for mediating LPA-stimulated cell growth in SKOV-3 and Caov-3 ovarian cancer cell lines.
METHODS: Pharmacological inhibitors of distinct LPA and epidermal growth factor receptors, G proteins and kinases were tested for their effect on LPA-stimulated cell growth, MAP kinase activation and Akt activation in SKOV-3 and Caov-3 cells.
RESULTS: Distinct agonist pharmacological profiles were observed. Saturated and unsaturated LPA species were equally potent in Caov-3 cells, while saturated LPA was less potent than unsaturated LPA in SKOV-3 cells. Further, the LPA1/LPA3 receptor antagonist Ki16425 was more potent in SKOV-3 cells. The effect of LPA on cell growth in both cell lines was dependent on phosphatidylinositol-3 kinases and MAP kinases. However, LPA-stimulated SKOV-3 cell growth required Gi G proteins, while Caov-3 cell growth was dependent on the Rho effector p160 Rho kinase. Finally, we demonstrated that regulator of G protein signaling proteins significantly regulated Gi-dependent LPA-stimulated cell growth in SKOV-3 cells.
CONCLUSIONS: LPA-stimulated cell growth is mediated by distinct but overlapping receptors and signaling pathways in these two model ovarian cancer cell lines. Copyright 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19420982     DOI: 10.1159/000217582

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  7 in total

1.  Overexpression of microRNA-367 inhibits angiogenesis in ovarian cancer by downregulating the expression of LPA1.

Authors:  Qingling Zheng; Xin Dai; Wei Fang; Yan Zheng; Jin Zhang; Yanxiang Liu; Donghua Gu
Journal:  Cancer Cell Int       Date:  2020-10-02       Impact factor: 5.722

2.  Regulators of G-Protein signaling RGS10 and RGS17 regulate chemoresistance in ovarian cancer cells.

Authors:  Shelley B Hooks; Phillip Callihan; Molly K Altman; Jillian H Hurst; Mourad W Ali; Mandi M Murph
Journal:  Mol Cancer       Date:  2010-11-02       Impact factor: 27.401

3.  Dipalmitoylphosphatidic acid inhibits tumor growth in triple-negative breast cancer.

Authors:  Qian-Qian Zhang; Jian Chen; Da-Lei Zhou; You-Fa Duan; Cui-Ling Qi; Jiang-Chao Li; Xiao-Dong He; Min Zhang; Yong-Xia Yang; Lijing Wang
Journal:  Int J Biol Sci       Date:  2017-03-12       Impact factor: 6.580

Review 4.  The role of the microbiome in ovarian cancer: mechanistic insights into oncobiosis and to bacterial metabolite signaling.

Authors:  Adrienn Sipos; Gyula Ujlaki; Edit Mikó; Eszter Maka; Judit Szabó; Karen Uray; Zoárd Krasznai; Péter Bai
Journal:  Mol Med       Date:  2021-04-01       Impact factor: 6.354

5.  Transcriptional suppression, DNA methylation, and histone deacetylation of the regulator of G-protein signaling 10 (RGS10) gene in ovarian cancer cells.

Authors:  Mourad W Ali; Ercan Cacan; Yuying Liu; Jennifer Young Pierce; William T Creasman; Mandi M Murph; Rajgopal Govindarajan; Scott T Eblen; Susanna F Greer; Shelley B Hooks
Journal:  PLoS One       Date:  2013-03-22       Impact factor: 3.240

6.  Inhibition of HDAC1 and DNMT1 modulate RGS10 expression and decrease ovarian cancer chemoresistance.

Authors:  Ercan Cacan; Mourad W Ali; Nathaniel H Boyd; Shelley B Hooks; Susanna F Greer
Journal:  PLoS One       Date:  2014-01-27       Impact factor: 3.240

7.  Profiling lysophosphatidic acid levels in plasma from head and neck cancer patients.

Authors:  Mariati Abdul Rahman; Didi Erwandi Mohamad Haron; Robert J Hollows; Zuleen Delina Fasya Abdul Ghani; Mustafa Ali Mohd; Wen Lin Chai; Ching Ching Ng; Munn Sann Lye; Saiful Anuar Karsani; Lee Fah Yap; Ian C Paterson
Journal:  PeerJ       Date:  2020-06-05       Impact factor: 2.984

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.